Articles related to Pathology

Poor metabolizers of UGT1A1 face a significantly increased risk of severe neutropenia from irinotecan therapy, making genetic testing crucial for appropriate dose modification.

The combination of ponatinib and blinatumomab demonstrated a 95% complete response rate and 91% 3-year overall survival rate in patients with Ph-positive ALL.

The I-SPY2 trial demonstrates that novel treatment approaches can yield high pathologic complete response rates in rare histologic subtypes of high-risk breast cancer, potentially improving outcomes for these challenging cases.

The prevalence of low-grade inflammation in the general population complicates the interpretation of vitamin D levels, calling for a more nuanced approach to testing and supplementation.

AL amyloidosis presents a diagnostic challenge due to its varied symptoms, but advancements in therapeutic options, including CyBorD plus daratumumab and emerging antifibril monoclonal antibodies, offer hope for better patient management.

Recent findings suggest extending follow-up colonoscopy intervals to 15 years for patients without a family history of colorectal cancer and with initial negative results. This could reduce unnecessary procedures without significantly increasing cancer risk.